Pharmacokinetics of Daidzein 4′-Phenylsulfonyl Ester and Its Active Metabolite Daidzein Assayed by HPLC Method in Rats After Intravenous Administration and Oral Administration

Xue-Mei ZHU,Jiang-Ning HU
DOI: https://doi.org/10.29011/2575-7091.100001
2016-01-01
Abstract:To determine the pharmacokinetics of Daidzein 4′-Phenylsulfonyl Ester (DZPE) in rats, a validated HPLC method has been developed for the simultaneous determination of DZPE and its metabolite Daidzein (DZ) in rat plasma. DZPE and DZ were determined by reversed-phase HPLC system (column: Diamonsil C18, 5 μm silica, 200 × 4.6 mm i.d.; eluent: methanol and 0.1% formic acid aquatic solution, 1:1, v/v; detection wavelength: 262 nm) with genistein as the internal standard. The calibration curves were linear over the ranges of 19.8-19800 ng/ml for DZPE and 10.26-8208 ng/ml for DZ. The lower limits of detection were 9.64 ng/ml and 5.42 ng/ml for DZPE and DZ, respectively. The RSDs of intra-days and inter-days tests were less than 8.2% and the average recovery ranged from 86.6% to 94.4% for DZPE and 72.4% to 82.0% for DZ. Subsequently, the method was applied to the pharmacokinetic study of DZPE and DZ in rat’s plasma. About 30.6% of DZPE was converted into DZ after oral administration of DZPE in rats, while only 11.2% of DZPE was converted into DZ after intravenous administration of DZPE within 24 h. The absolute bioavailability of total DZPE and DZ was 31.6%. The method was demonstrated to be feasible for pharmacokinetic studies of DZPE in rats. Keywords: Daidzein; Daidzein 4′-Phenylsulfonyl ester; Pharmacokinetics; RP-HPLC
What problem does this paper attempt to address?